Israel’s Rosetta Genomics has received a US patent for the treatment of prostate cancer through the administration of anti-hsa-miR-210. High levels of hsa-miR-210 indicate the presence of prostate cancer and treatments to reduce it may cure the disease.

http://www.rosettagenomics.com/news/rosetta-genomics-receives-u-s-patent-for-treatment-of-prostate-cancer